Davunetide clinical trials
Also written AL-108.
How each study uses davunetide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Allon Therapeutics (3) · University of California, San Francisco (1) · University of California, Los Angeles (1)
Studies
Open first, then newest update. How each study uses davunetide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyCompletedPhase 1University of California, San FranciscoNCT01056965Written as davunetide (AL-108, NAP)
- A Multicenter Study of NAP (AL-108) in SchizophreniaCompletedPhase 2University of California, Los AngelesNCT00505765Written as AL-108
- Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyCompletedPhase 2/3Allon TherapeuticsNCT01110720Written as Davunetide
- Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive ImpairmentCompletedPhase 2Allon TherapeuticsNCT00422981Written as AL-108
- Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft SurgeryCompletedPhase 2Allon TherapeuticsNCT00404014Written as AL-208
Codes
What other systems call davunetide · ClinicalTrials.gg INT004338
- MeSH (NLM) C425904davunetideOne source NLM
- UNII (FDA) GF00K3IIWEDAVUNETIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27279075davunetideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169878DavunetideOne source FDA
- DrugBank DB12613One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C425904 | davunetide | One source NLM |
| UNII (FDA) | GF00K3IIWE | DAVUNETIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27279075 | davunetide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169878 | Davunetide | One source FDA |
| DrugBank | DB12613 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.